GlassScriptPhysician profile
Kambria Warnock
NPI 1801668447
$2,584.89
in general payments reported to CMS, 2019-2025
28 companies · $2,100 in 2025
The $2,100 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $121 · 2024: $364 · 2025: $2,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $544.29 | 2024-2025 | |
| Amgen INC. | $375.35 | 2024-2025 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $297.71 | 2025 | Rexulti |
| Novo Nordisk INC | $249.17 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $218.91 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $117.33 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Daiichi Sankyo INC. | $102.71 | 2023 | Injectafer |
| Pfizer INC. | $82.26 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $58.37 | 2025 | Voquezna |
| Lilly USA, LLC | $55.00 | 2024-2025 | Jardiance |
| Lundbeck LLC | $47.65 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.07 | 2024-2025 | Xifaxan, Trulance, Relistor |
| Astellas Pharma US INC | $40.71 | 2025 | Veozah |
| Dexcom, INC. | $36.03 | 2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $35.48 | 2024-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.60 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.04 | 2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $27.99 | 2025 | Zoryve |
| Exact Sciences Corporation | $24.98 | 2025 | Cologuard Collection Kit |
| Agios Pharmaceuticals, INC. | $24.94 | 2025 | Pyrukynd |
| Merck Sharp & Dohme LLC | $20.53 | 2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Organon LLC | $18.32 | 2023 | Nexplanon |
| Novocure INC. | $18.29 | 2025 | Optune Lua (Novottf-200t) |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.66 | 2025 | Caplyta |
| Corium, LLC | $17.49 | 2024 | Azstarys |
| Lexicon Pharmaceuticals, INC. | $16.47 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.95 | 2025 | |
| Noven Therapeutics, LLC | $14.59 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kambria Warnock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.